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Abstract
Background: FOXP2 is a forkhead transcription factor critical for normal development of language
in humans, but little is known of its broader function and regulation during central nervous system
(CNS) development. We report here that lef1, a member of the Lef/Tcf family of transcription
factors activated by Wnt signaling, regulates foxP2 during embryogenesis, and we isolate novel foxP2
enhancers which are lef1-dependent.
Results: Loss, knock down, or inhibition of lef1 led to loss of foxP2 expression. We isolated DNA
fragments from the foxP2 genomic region that function as enhancers to drive GFP expression in the
CNS during development, including in the telencephalon, diencephalon, eye, tectum, and hindbrain.
Three of these enhancers, foxP2-enhancerA.1, foxP2-enhancerB, and foxP2-enhancerD, contain
putative Lef1 binding sites, and are regulated by lef1. However, two other genomic fragments
containing Lef1 sites failed to function in vivo as enhancers. Chromatin immunoprecipitation
confirmed that Lef1 binds to sites in foxP2-enhancerA.1 and foxP2-enhancerB.
Conclusion: This work shows that lef1 is necessary for expression of foxP2 in the tectum, mid-
hindbrain boundary, and hindbrain during CNS development, and is the first insight into the
upstream regulation of foxP2 during development. We also demonstrate that in silico prediction of
potential lef1 binding sites poorly predicts their ability to function in vivo as enhancers. The foxP2
enhancers we identified will allow dissection of foxP2's role during CNS development.
Background
FOXP2 is a forkhead domain transcription factor whose
mutation has been associated with severe deficits in lan-
guage [1-6]. Its cloning and expression during develop-
ment have been described in humans, mouse, songbird,
frog, medaka, and zebrafish [7-16]. CNS expression dur-
ing development in the different vertebrate species is
remarkably similar, with conserved expression in the tel-
encephalon, basal ganglia, thalamus, tectum, tegmentum,
cerebellum, and hindbrain. However, the function of
FOXP2 during CNS development is poorly understood.
Homozygous knockout or point mutation of Foxp2 in
mice leads to early postnatal death, with reports of disor-
dered Purkinje cell layers [17-19] and smaller cerebellar
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size [18,20]. In songbirds, FoxP2 appears to be necessary
for vocal learning and is expressed in neurons during
active song learning [9,21,22].
The neural circuits and genetic cascades in which FOXP2
participates remain uncharacterized. Chromatin immu-
noprecipitation methods have identified potential down-
stream targets of FOXP2 [23,24], but in vivo function and
importance of the identified targets is uncertain. To
understand in greater detail the role of foxP2  in CNS
development, we sought to identify how foxP2 expression
is regulated. The conservation of six predicted lef1 binding
sites between pufferfish, zebrafish, mouse, and human in
the foxP2 genomic region (this study; [25], and the over-
lapping expression of lef1 and foxP2 in the zebrafish CNS
during development, led us to consider whether lef1
might regulate foxP2. Lef1 is a transcription factor acti-
vated by the canonical Wnt/β-catenin signaling pathway,
which has been shown to play a critical role in prolifera-
tion, tissue patterning, CNS neuronal cell fate specifica-
tion, and axon pathfinding [26]. We found that loss or
knockdown of lef1 led to a loss of foxP2 expression in the
tectum, mid-hindbrain boundary, and hindbrain. Of six
conserved potential lef1  binding sites predicted in the
foxP2 genomic region [25], we show that only three lie in
genomic fragments that function in vivo as enhancers,
underscoring the importance of in vivo testing of predicted
enhancers. Using chromatin immunoprecipitation
(ChIP), we demonstrated that lef1 can bind directly to the
functional enhancer sites, and showed that in the absence
of lef1 these enhancers fail to function. The foxP2 enhanc-
ers will be useful for dissection of foxP2 function by allow-
ing detailed analysis of axon pathfinding and
synaptogenesis in foxP2-expressing neurons.
Results
foxP2 and lef1 have sequential and overlapping 
expression in the CNS during embryogenesis
We noted that 6 binding sites for Tcf/Lef transcription fac-
tors are conserved between mouse and pufferfish in the
FOXP2 genomic region, which is more than for any other
putative Tcf/Lef target gene (Table S6 of [25]. This finding,
and our prior observations that foxP2  and  lef1  are
expressed in the tectum and hindbrain during CNS
embryogenesis [7,27], raised the possibility that lef1
might regulate foxP2  expression. We performed in situ
labeling for foxP2  and  lef1  to investigate whether they
shared temporal and/or spatial domains of expression.
We found that lef1  is expressed in the mid-hindbrain
boundary (MHB) starting at 24 hpf, and in the tectum
starting at 30 hpf (Figure 1A–C). foxP2 expression in the
MHB and tectum becomes apparent at 36 hpf (Figure 1D–
Sequential expression of foxP2 and lef1 in the CNS during embryogenesis Figure 1
Sequential expression of foxP2 and lef1 in the CNS during embryogenesis. Whole-mount in situs for lef1 (A-C) and 
foxP2 (D-F) at 24 hpf, 30 hpf, and 36 hpf. Lateral views, anterior to left, dorsal up; eyes have been removed to facilitate visuali-
zation. Scale bar = 50 μm. (Abbreviations: dd, dorsal diencephalon; hb, hindbrain; hy, hypothalamus; mhb, mid-hindbrain bound-
ary; tec, tectum; tel, telencephalon.) (A-C): lef1 is expressed in the hypothalamus, dorsal midbrain, and MHB at 24 hpf, with 
expression extending to the tectum at 30 hpf. By 36 hpf expression is confined primarily to the hypothalamus and tectum. (D-
F): foxP2 is expressed in the tectum and MHB starting at 36 hpf. Earlier expression (24 hpf and 30 hpf) is confined to the telen-
cephalon.BMC Developmental Biology 2008, 8:103 http://www.biomedcentral.com/1471-213X/8/103
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F). Other domains of lef1 and foxP2 expression, including
the telencephalon, hypothalamus, and dorsal dien-
cephalon, had non-overlapping expression. To confirm
that foxP2 and lef1 are indeed co-expressed in the same
cells, rather than in distinct subsets of cells in the same
region, we performed double in situs, and found that foxP2
and lef1 are co-expressed in tectal cells at 36 hpf (Figure
2A–D). This sequentially overlapping pattern of expres-
sion in the MHB, and contemporaneous overlap in the
tectum, confirmed that lef1 was present in a relevant pat-
tern to potentially direct foxP2 expression.
Knockdown of lef1 causes loss of foxP2 expression
Based on this overlap of expression, we hypothesized that
lef1  might regulate foxP2. To test this, we used several
approaches. First, we used a morpholino to knockdown
lef1 [27], and evaluated foxP2 in situ expression. Knock-
down of lef1 causes a near-complete loss of foxP2 expres-
sion in the tectum, MHB, and hindbrain at 36 hpf (Figure
3A, B) in 85% of injected embryos (n = 61), compared
with 0% of uninjected embryos (n = 53). This effect is spe-
cific to lef1, since a morpholino against a different Lef/Tcf
family member, tcf3b [28], which is also expressed in the
tectum and hindbrain [28], showed no effect on foxP2
expression (n = 48, data not shown). The loss of foxP2
expression in the hindbrain, where lef1 expression is not
detectable by in situ (Figure 1A–C), is presumably an indi-
rect effect, perhaps via loss of an inductive signal from the
MHB. Alternatively, this could be a direct effect, for exam-
ple, if lef1 is expressed at very low levels in the hindbrain,
or if some lef1-positive neurons migrate from the MHB to
the hindbrain.
To confirm that loss of foxP2 expression was due to knock-
down of lef1 and not a non-specific morpholino effect, we
utilized two alternative means to remove lef1 expression.
Co-expression of foxP2 and lef1 in the tectum Figure 2
Co-expression of foxP2 and lef1 in the tectum. Whole-mount double in situ confocal imaging for foxP2 and lef1 at 36 hpf, 
dorsal views, anterior up. Abbreviations: hb, hindbrain; tec, tectum; tel, telencephalon. (A) Z-stack projection of foxP2 (green) 
overlaid on brightfield image of lef1 expression in the tectum. The region shown in higher magnification in (B-D) is boxed in 
yellow. Scale bar = 50 μm. (B-D) Single optical plane showing lef1 (red- BM Purple), foxP2 (green- Alexa 488), and co-expres-
sion in the tectum. Arrow points to a representative co-expressing cell. Scale bar = 25 μm.BMC Developmental Biology 2008, 8:103 http://www.biomedcentral.com/1471-213X/8/103
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Loss of lef1 leads to absent foxP2 expression in the tectum, mid-hindbrain boundary, and hindbrain Figure 3
Loss of lef1 leads to absent foxP2 expression in the tectum, mid-hindbrain boundary, and hindbrain. Whole-
mount in situs at 36 hpf; anterior to left, dorsal up, eyes removed. Scale bar = 50 μm. (Conditions: hs:Δtcf, Tg(hsp70l:Δtcf-
GFP)w26; lef1 mo, lef1 morphants; wt, wild type; x8, homozygous Df(LG01)x8. Abbreviations: hb, hindbrain; mhb, mid-hindbrain 
boundary; tec, tectum; tel, telencephalon.) (A, B) lef1 morphant (B) lacks expression in tectum, MHB, and hindbrain (arrows), 
compared to wild-type (A). (C) Df(LG01)x8 homozygote lacks expression in tectum, MHB, and hindbrain (arrows). (D) 
Tg(hsp70l:Δtcf:GFP)w26 embryo, three hours post-heat shock, lacks expression in tectum, MHB, and hindbrain (arrows). (E, F) 
mbx in situs; staining in tectum and hindbrain is indistinguishable between wild type and lef1 morphants (F).BMC Developmental Biology 2008, 8:103 http://www.biomedcentral.com/1471-213X/8/103
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First, we examined expression of foxP2  in Df(LG01)x8
mutant embryos. Df(LG01)x8 is a deletion on chromo-
some 1 which contains lef1 (but not foxP2); homozygous
deficiency mutants do not express lef1 [27,29]. We found
that homozygous Df(LG01)x8  mutants do not express
foxP2  in the tectum, MHB, or hindbrain (Figure 3C)
(100%, n = 25 embryos).
Second, we examined whether a dominant negative con-
struct which inhibits lef1 function would cause a loss of
foxP2 expression. We used embryos carrying the transgene
hsp70l:Δtcf-GFP, which expresses an N-terminal deletion
of Tcf3a fused to GFP. In the absence of its N-terminal
DNA-binding domain, Tcf3a acts as a dominant repressor
of Wnt-mediated transcription [30]. Following heat-shock
at 32 hpf for 1 hour, embryos were collected 3 hours post-
heat shock. There was loss of foxP2 expression in the tec-
tum, MHB, and hindbrain (Figure 3D) in 61% of trans-
genic embryos (n = 38), and in 0% of non-transgenic
siblings (n = 82). Decrease of foxP2 telencephalic expres-
sion is presumably due to a dominant effect of the trans-
gene, since the decrease was not seen using the
morpholino or Df(LG01)x8.
The loss of foxP2 expression in the tectum and hindbrain
is not secondary to an absence of cells, as expression of the
tectal marker mbx [31] is indistinguishable between wild
type and lef1 morphants (Figure 3E, F). Other markers for
the tectum (emx2), and hindbrain (isl1, zash1a) of lef1
morphants also appear as wild type patterns and levels
[27]; J.E.L. and R.I.D., unpublished data). Furthermore,
the loss of foxP2 expression persists at 48 hpf (Additional
File 1). These results show that loss of lef1 specifically
causes loss of foxP2 expression in the tectum, MHB, and
hindbrain.
Identification of foxP2 genomic enhancers and Lef1 
binding sites
6 potential conserved binding sites for lef/tcf family tran-
scription factors were identified in the FOXP2 genomic
locus of mouse and pufferfish using in silico analysis [25].
This algorithm (enhancer element locator) aligns tran-
scription factor sequence sites from orthologous genomic
regions between two species, with scoring of the sites
determined by conservation, affinity, and clustering of
sites. Based on conserved synteny between zebrafish,
mouse, and pufferfish, we initially were able to identify 5
of these sites in the zebrafish foxP2 genomic locus using
Sanger Centre genome assembly Zv6 (see Methods; Figure
4A).
Because the foxP2 genomic assembly is incomplete in the
region upstream of the 2nd coding exon (J.L.B., unpub-
lished data), we sought to identify the sixth predicted lef1
binding site. In human FOXP2 this site is 8.8 kb upstream
of the first coding exon. We obtained the sequence for this
region in zebrafish from the unassembled BAC DKEY-
116L11. Using the enhancer element locator algorithm
[25], we compared the 9 kb regions immediately
upstream of the first coding exon of foxP2  from the
human and zebrafish genomes. We found conservation of
this same element (zebrafish: ttgtgggctGCTTTCATCtgt-
gggttaa; human: atgatcagtGCTTTCATCtttattttaa) located
8.5 kb upstream of the first coding exon in zebrafish (con-
tained within foxP2-enhancerA).
To identify foxP2 enhancers, and to determine whether
any of the potential lef1 sites might function in vivo in the
context of enhancer elements, we cloned genomic frag-
ments containing the sites into a Tol2 transposon-based
vector (Figure 4B) [32-34]. To visualize expression con-
trolled by the potential enhancers, each DNA fragment
was cloned immediately upstream of GFP under control
of a minimal promoter [32]. In total we cloned nine
genomic DNA fragments (Figure 4A), from five different
regions, containing the six predicted lef1 sites (two sites
are contained in foxP2-fragmentC). To test for expression,
we injected one cell stage embryos and assayed GFP
expression from 12 hpf through 96 hpf (Figure 4C). Sub-
sequent analysis used stable transgenic lines, which
mostly reproduced the same patterns of expression. Three
of the regions, foxP2-enhancerA, B, and D, drove GFP
expression in patterns partially recapitulating foxP2
expression (Figure 5). Potential enhancers foxP2-frag-
mentC and foxP2-fragmentE had no expression.
foxP2-enhancerA drove expression in the eye, dien-
cephalon, tectum, hindbrain, and telencephalon (Figure
5A, B). GFP expression was first noted in the telen-
cephalon at 24 hpf, then at 48 hpf in the eye, tectum and
hindbrain, becoming maximal at 72 hpf. By 80 hpf
expression in the CNS diminished significantly, while jaw
expression became visible. Subcloning of foxP2-
enhancerA to yield enhancerA.1 and A.2 revealed very
similar patterns to foxP2-enhancerA (Figure 5C–F). How-
ever, enhancerA.2 had significantly fewer labeled cells,
suggesting that the more proximal region of enhancerA
and enhancerA.1 contains necessary elements. foxP2-
enhancerB expression in the telencephalon began at 24
hpf, with eye and hindbrain expression apparent by 72
hpf (Figure 5G, H). foxP2-enhancerD expression in the
eye, dorsal diencephalon, and tectum began at 36 hpf, was
maximal at 48 hpf, and decreased by 72 hpf (Figure 5I, J).
The enhancers we have identified partially mirror endog-
enous foxP2 expression [7]. While the enhancer fragments
were chosen based on in silico prediction of potential lef1
binding sites [25], our analysis shows the importance of in
vivo validation, since only 3 of the 6 predicted bindingBMC Developmental Biology 2008, 8:103 http://www.biomedcentral.com/1471-213X/8/103
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sites appear to lie in functional enhancer elements for the
stages analyzed.
lef1 knockdown leads to loss of expression from foxP2-
enhancers A.1, B, and D
Based on our observations that foxP2-enhancers A.1, B,
and D show expression in a pattern mirroring lef1 expres-
sion in the tectum and hindbrain, and contained putative
binding sites for Lef1, we tested whether knockdown of
lef1 led to loss of GFP expression. We injected lef1 mor-
pholino into stable transgenic foxP2  enhancer lines
(Tg(foxP2-enhancerA.1:EGFP)zc44, Tg(foxP2-enhancerB:EGF
P)zc41, Tg(foxP2-enhancerD:EGFP)zc47), and looked for GFP
expression in the tectum and hindbrain at 36 hpf. To
detect enhancer-driven transcription with maximum sen-
sitivity, we used an in situ probe for gfp. Morphants
showed a loss of GFP expression in the tectum and hind-
brain, but maintenance of telencephalic expression, in
89% of enhancerA.1 embryos (n = 71), 100% of
enhancerB embryos (n = 22), and 100% of enhancerD
embryos (n = 27) (Figure 6A–F). In contrast, in uninjected
embryos only 2%, 0%, and 0% (n = 58, 15, and 16),
respectively, showed loss of tectum and hindbrain expres-
sion. Further, the lef1-mediated loss of expression from
the enhancers was visible at 52 hpf by visualization of
GFP (Additional File 2).
To demonstrate that loss of GFP expression in the lef1
morphants was not simply due to absence of the GFP-
expressing cells, we injected lef1 morpholino into trans-
genic fish lines Tg(elavl3:EGFP)zf8  (also known as
HuC:GFP) and Tg(pax2a:GFP)e1. Tg(elavl3:EGFP)zf8
expresses GFP in all post-mitotic neurons [35], while
Tg(pax2a:GFP)e1  expresses GFP in a pattern mirroring
pax2a expression, including in the MHB, cerebellum, and
hindbrain [36]. In both lines we found that lef1  mor-
phants still expressed GFP in the tectum, MHB, and hind-
brain (Figure 6G, H, and Additional File 2). In addition,
using Tg(isl3:GFP)zc7 to label retinal axons (A. Pittman
and C.B.C., unpublished), we observed that the pattern of
retinotectal projections appeared normal in 48 hpf mor-
phants (data not shown). Although overall numbers of
GFP-expressing cells appeared reduced in lef1 morphants
of Tg(elavl3:EGFP)zf8 and Tg(pax2a:GFP)e1, in the foxP2
enhancer lines there was a complete lack of GFP-express-
ing cells in the tectum and hindbrain. These results show
Genomic structure and identification of enhancers of foxP2 Figure 4
Genomic structure and identification of enhancers of foxP2. (A) foxP2 genomic region (not to scale). Coding exons are 
shown as solid black boxes. Predicted lef1 binding sites are shown as ovals. DNA fragments tested for enhancer activity are 
shown. (B) Schematic of cloning strategy for DNA fragments. PCR primers for the genomic region of interest (red box) are 
designed with attB4 and attB1 sites (blue boxes), and the region is amplified and cloned using a BP reaction into an entry clone. 
A LR reaction is performed to recombine the entry clone (containing the genomic DNA fragment) into a Tol2 destination vec-
tor, placing the genomic fragment upstream of a basal promoter and EGFP (green box). (C) Summary table of expression pat-
terns of the different enhancers at 72 hpf in the CNS.BMC Developmental Biology 2008, 8:103 http://www.biomedcentral.com/1471-213X/8/103
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Confocal live whole-mount images of foxP2 enhancers Figure 5
Confocal live whole-mount images of foxP2 enhancers. Pictures show GFP expression at 72 hpf (except foxP2-enhanc-
erD, taken at 48 hpf). The eye has been removed in panels E and G to facilitate visualization. Scale bar = 100 μm. (A, C, E, G, 
I): lateral views, anterior left, dorsal up. (B, D, F, H, J): dorsal views, anterior up. (Abbreviations: di, diencephalon; hb, hindbrain; 
tec, tectum; tel, telencephalon; arrows, GFP-expressing cells in the eye. (A, B) Tg(foxP2-enhancerA:EGFP)zc42; (C, D) Tg(foxP2-
enhancerA.1:EGFP)zc44; (E, F) Tg(foxP2-enhancerA.2:EGFP)zc46; (G, H) Tg(foxP-enhancerB:EGFP)zc41; (I, J) Tg(foxP2-enhanc-
erD:EGFP)zc47.BMC Developmental Biology 2008, 8:103 http://www.biomedcentral.com/1471-213X/8/103
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Figure 6 (see legend on next page)BMC Developmental Biology 2008, 8:103 http://www.biomedcentral.com/1471-213X/8/103
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that loss of tectal and hindbrain expression observed with
the  lef1  morpholino in foxP2-enhancerA.1, foxP2-
enhancerB, and foxP2-enhancerD is not simply due to a
loss of neurons, but instead indicates a requirement for
lef1 in these enhancers' function.
Chromatin immunoprecipitation identifies critical Lef1 
binding sites in foxP2-enhancerA.1 and foxP2-enhancerB
To test whether Lef1 can bind to foxP2-enhancerA.1 and
foxP2-enhancerB to regulate foxP2  expression, we per-
formed chromatin immunoprecipitation (ChIP) using a
polyclonal antibody against zebrafish Lef1 [27]. We
designed PCR amplicons to test different regions of foxP2-
enhancerA.1 and foxP2-enhancerB (Figure 7A), using
chromatin extracted from 30 hpf embryos. For foxP2-
enhancerA.1, we found that PCR amplicon FP2700 (cen-
tered around base pair 2700 in the enhancerA.1 DNA frag-
ment) showed significant enrichment compared to
controls (no antibody, and extracts from homozygous
Df(LG01)x8 embryos) (Figure 7B). Interestingly, amplicon
FP300, encompassing the predicted Lef1 binding site in
foxP2-enhancerA.1 (Figure 7A), showed minimal enrich-
ment (Figure 7B). Further, a deletion construct of foxP2-
enhancerA:GFP, removing the region containing FP300,
did not cause loss of GFP expression (data not shown).
This suggests that maximal Lef1 binding for foxP2-
enhancerA.1 is centered around FP2700. For foxP2-
enhancerB, we found that FPb2600 had significant
enrichment compared to controls (Figure 7C). This PCR
amplicon contains a predicted Lef1 binding site [25] (Fig-
ure 7A). We therefore conclude that Lef1 directly interacts
with regulatory regions of foxP2  in 30 hpf zebrafish
embryos.
Discussion
Our data show that lef1 and foxP2 expression overlap in
the developing CNS, and that lef1 is necessary for foxP2
expression in the tectum, MHB, and hindbrain. We iden-
tified Lef1binding sites in the foxP2 regulatory regions,
based on the identification of foxP2  enhancers that
depend on lef1 for expression, and ChIP analysis showing
binding of Lef1 to these enhancers.
lef1 regulation appears to be a combination of both direct
and indirect effects on foxP2 (Figure 8). In the tectum and
MHB, lef1 expression precedes foxP2 expression. Loss of
lef1 leads to loss of both endogenous foxP2 expression,
and expression from foxP2 enhancers. In the hindbrain
loss of lef1 also leads to a loss of foxP2 expression. Since
lef1  expression is not detectable in the hindbrain, we
hypothesize that loss of foxP2 expression occurs both via
an inductive effect of lef1 expression in the MHB, and
through a second gene regulated by lef1 (Figure 8). This
model would explain why we observe foxP2 expression
(both by in situ and by expression from its enhancers) in
the hindbrain (where lef1 is not expressed), as well as why
foxP2 expression persists after lef1 expression in the MHB
stops. In addition, our data demonstrate that foxP2 expres-
sion in the telencephalon, including the subpallium/basal
ganglia, is regulated independently of lef1.
Since foxP2 expression in the telencephalon is not lef1-
dependent, other factors must regulate foxP2. Conversely,
in regions where lef1 is expressed but foxP2 is not, for
example the dorsal diencephalon, lack of foxP2 expression
could either reflect an absence of some necessary co-fac-
tors, or the presence of an inhibitor of expression, or both
mechanisms. We have tried to globally activate foxP2 by
heat-shock induction of a constitutively active form of tcf3
(RID, unpublished data), but did not observe any ectopic
foxP2 expression (data not shown), implying stringent,
multifactorial control of foxP2 expression.
Previous computer algorithm-based methods identified
several other potential Lef1 binding sites in the foxP2
genomic region [25], but our in vivo analysis failed to sup-
port a role for them. Another recently described in silico
method to identify transcription factor target genes would
also fail to identify the lef1 enhancers for foxP2, as this
method only included the 5 kb regions immediately
upstream of transcriptional start sites [37]. Our work
lef1 is necessary for expression from foxP2-enhancerA.1, foxP2-enhancerB, and foxP2-enhancerD Figure 6 (see previous page)
lef1 is necessary for expression from foxP2-enhancerA.1, foxP2-enhancerB, and foxP2-enhancerD. Whole-
mount gfp in situs at 36 hpf; anterior to left, dorsal up, eyes removed. Scale bar = 50 μm. Conditions (wild type, wt; or lef1 
morphant, lef1 MO) are shown above the panels, enhancer names to left. (Abbreviations: dd, dorsal diencephalon; hb, hind-
brain; tec, tectum; tel, telencephalon.) (A) Tg(foxP2-enhancerA.1:EGFP)zc44 expresses in telencephalon, tectum, and hindbrain. (B) 
Tg(foxP2-enhancerA.1:EGFP)zc44 embryo injected with lef1 morpholino lacks GFP expression in tectum and hindbrain (arrows), 
although telencephalic expression persists. (C) Tg(foxP2-enhancerB:EGFP)zc41 expresses in telencephalon and hindbrain. (D) 
Tg(foxP2-enhancerB:EGFP)zc41 embryo injected with lef1 morpholino lacks GFP expression in the hindbrain (arrow), but telen-
cephalic expression is present. (E) Tg(foxP2-enhancerD:EGFP)zc47 expresses in dorsal diencephalon and tectum. (F) Tg(foxP2-
enhancerD:EGFP)zc47 embryo injected with lef1 morpholino lacks GFP expression in the tectum (arrow), but dorsal diencephalic 
expression persists. (G) Tg(elavl3:EGFP)zf8 embryo shows GFP expression in all post-mitotic neurons. (H) Tg(elavl3:EGFP)zf8 
embryo injected with lef1 morpholino still has GFP expression in the tectum and hindbrain.BMC Developmental Biology 2008, 8:103 http://www.biomedcentral.com/1471-213X/8/103
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ChIP analysis of foxP2-enhancerA.1 and foxP2-enhancerB genomic regions at 30 hpf Figure 7
ChIP analysis of foxP2-enhancerA.1 and foxP2-enhancerB genomic regions at 30 hpf. (A) Diagram of foxP2-
enhancerA.1 and foxP2-enhancerB regions. PCR amplicon locations and names are indicated above the genomic region; pre-
dicted Lef1 binding sites are shown as ovals. (B) Agarose gel analysis of ChIP PCR for foxP2-enhancerA.1, showing the PCR 
products for FP2700, FP300, and B3end. In wild type (wt) embryos, ChIP shows significant enrichment of the FP2700 product 
and slight enrichment of the FP300 product, compared to both the no antibody (Ab) control, and the ChIP of homozygous 
Df(LG01)x8 embryos (Mock: water control for the PCR reaction.) In contrast, the B3end product showed no enrichment rela-
tive to the Df(LG01)x8 embryos. (C) Agarose gel analysis of ChIP PCR for foxP2-enhancerB, showing the FPb2600 PCR prod-
uct. In wt embryos, ChIP shows significant enrichment of the FPb2600 product, compared to both the no antibody and 
homozygous Df(LG01)x8 controls.BMC Developmental Biology 2008, 8:103 http://www.biomedcentral.com/1471-213X/8/103
Page 11 of 15
(page number not for citation purposes)
shows the importance of actual in vivo testing for analysis
of enhancer gene regulation.
Since we analyzed expression up to 96 hours after fertili-
zation, enhancers responsible for controlling expression
at later times might have been missed. Given that all of the
CNS domains of expression for foxP2 are present by 72
hpf [7,11], we feel that this is unlikely. However, we can
not exclude the possibility that untested genomic regions
might regulate expression, or that several independent
regions might function in concert.
This study identified three regions functioning as enhanc-
ers for foxP2, specifically driving expression in the telen-
cephalon, eye, diencephalon, tectum, and hindbrain.
Their expression reveals that foxP2 is expressed in multiple
brain regions, under strict temporal and spatial control,
regulated through both lef1-dependent and -independent
mechanisms. These transgenic lines label multiple distinct
axon tracts (data not shown), and will allow analysis of
subsets of foxP2 neurons and axons, in both wild type and
mutant backgrounds, as well as misexpression and rescue
experiments.
The role of foxP2 in CNS development has remained elu-
sive, despite multiple genetic studies in humans demon-
strating its necessity for normal language development [1-
6]. In affected members of the human KE family, who
carry a heterozygous point mutation which disrupts the
function of one copy of FOXP2, voxel-based morphomet-
ric MRI analyses suggest disturbances in Broca's area, the
basal ganglia, and the cerebellum [38,39]. Studies of
FoxP2 knockout or point mutation mice have consistently
shown cerebellar involvement. Homozygotes have been
reported to have disordered Purkinje cell layering [17-
19,40] and smaller cerebellar size [18,20], while heterozy-
gotes are noted to display impaired motor learning and
altered Purkinje cell synaptic plasticity [19,20]. Our iden-
tification of lef1 as a regulator of foxP2 expression in the
MHB and hindbrain is a first step towards understanding
the foxP2 genetic network involved in cerebellar develop-
ment. The role of the cerebellum in language function is
at least partially understood [41], but it is uncertain
whether the oromotor apraxia of the KE family is due to
defects of cerebellar or striatal pathways (or both)
[40,42,43]. Importantly, other domains of foxP2 expres-
sion, for example in the telencephalon (including the sub-
pallium), appear to be regulated independently of lef1.
Conclusion
Wnt signaling has multiple roles in neuronal specification
and the development of connectivity in the CNS [26], as
does lef1, which is activated by the canonical Wnt signal-
ing cascade. lef1 is necessary for development of dentate
gyrus neurons [44], for neurogenesis and specification of
neuronal subsets in the hypothalamus [27], and for
expression of the transcription factors zic2a and zic5 in the
tectum [45]. Here we show that lef1 regulates foxP2 expres-
sion in the tectum, MHB, and hindbrain. Interestingly,
ChIP studies suggest that FOXP2  may in turn regulate
components of the Wnt signaling pathway [23,24]. The
identification of components of the foxP2 signaling cas-
cade, including upstream, interacting, and downstream
members, will be important for understanding foxP2 func-
tion, and for elucidating the genes and neural circuits
involved in language development.
Methods
Fish stocks and embryo raising
Adult fish were bred according to standard methods.
Embryos were raised at 28.5°C in E3 embryo medium
with 0.003% phenylthiourea to inhibit pigment forma-
tion and staged by time and morphology [46]. For in situ
staining, embryos were fixed in 4% paraformaldehyde
Model of foxP2 regulation in the CNS Figure 8
Model of foxP2 regulation in the CNS. In the telencephalon, an unknown factor X activates foxP2 expression. In the tec-
tum (and MHB) Lef1 directly binds to enhancer elements of foxP2, leading to foxP2 expression. In the hindbrain expression of 
foxP2 is Lef1-dependent, but indirectly, since Lef1 is not expressed in the hindbrain.BMC Developmental Biology 2008, 8:103 http://www.biomedcentral.com/1471-213X/8/103
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(PFA) (in PBS) for 3 h at room temperature (RT) or over-
night (O/N) at 4°C, washed briefly in PBS, dehydrated,
and stored in 100% MeOH at -20°C until use.
Transgenic fish lines and alleles used were as follows:
Df(LG01)x8  [29]; Tg(hsp70l:Δtcf-GFP)w26  [30]; Tg(foxP2-
enhancerA:EGFP)zc42; Tg(foxP2-enhancerA.1:EGFP)zc44;
Tg(foxP2-enhancerA.2:EGFP)zc46; Tg(foxP2-enhancerB:EGF
P)zc41; Tg(foxP2-enhancerD:EGFP)zc47; Tg(pax2a:GFP)e1
[36]; Tg(elavl3:EGFP)zf8  [35]. Df(LG01)x8  homozygotes
were identified by their smaller forebrain and flattened
hindbrain phenotype (J.E.L. and R.I.D., unpublished).
Tg(hsp70l:Δtcf-GFP)w26 embryos were identified by GFP
expression after heat shock.
Heat shock was performed by incubation of 32 hpf
embryos for 1 hour at 37°C, then collecting 3 hours after
the end of the heat shock.
In situ hybridization
Whole-mount in situ labeling for foxP2, gfp, and lef1 was
performed as previously described [7,27,47]; the mbx RNA
probe derived from full-length mbx  cDNA cloned into
pBluescript [31]. Double in situs were performed using a
DNP-labeled probe for foxP2  and digoxigenin-labeled
probe for lef1. Following standard hybridization and
washes, DNP probe was detected using an anti-DNP HRP
conjugate diluted 1:200 in TNTB block at 4°C overnight
(PerkinElmer; [48]), followed by detection using Alexa
Fluor 488 Tyramide diluted 1:250 (Molecular Probes)
with 0.0015% hydrogen peroxide for 1 hour. Embryos
were washed in TNT, blocked in TNTB, incubated with
anti-digoxigenin alkaline phosphatase diluted 1:5000 in
TNTB at 4°C overnight, and then detected with a standard
BM Purple color reaction.
Genomic PCR and Enhancer Cloning
PCR primers to clone foxP2 genomic fragments were as
follows (forward and reverse primers, sequences 5' to 3';
size in kb listed immediately following the enhancer
name): foxP2-enhancerA (9.7 kb): FP2.12L GTCGTAATT-
GCTCGGTGAC, FP2.3R GTGTGAATGCCAGCGATAGA;
foxP2-enhancerA.1 (6.8 kb): FP2.12L, FP2.16R CGTCTC-
GACTGAGCAGAGTT; foxP2-enhancerA.2 (5.1 kb):
FP2.12L, FP2.46R ACAACTGGCGTGTAAGGTGT; foxP2-
fragment A.3 (4.7 kb): FP2.41L GACACCTTA-
CACGCCAGTTG, FP2.3R; foxP2-fragment A.4 (2.3 kb):
FP2.41L, FP2.40R CAGGGTGTGTTATAAACATGCAT;
foxP2-enhancerB (4.6 kb): FP2.39L GACACTCTGGAG-
GAACTATG, FP2.38R GGAAACGGTGCAGTATGTGT;
foxP2-fragment C (1.6 kb): F.FP1 GGCGGGTACCTGGT-
CATATT, F.RP2 TTTCCACCCAACCATAAATCA; foxP2-
enhancerD (1.2 kb): H.FP1 CCAGCTATCCGAGAGGT-
TCA, H.RP2 CCGCCTGTTCAAATCAGAAT; foxP2-frag-
ment E (0.69 kb): G.FP1 TGACCTCTGTGTAGCCTTGC,
G.RP2 CATTGCTAGGGGAACGTGAT.
PCR was performed using standard conditions (TaKaRa
LA PCR amplification kit 2.1, Millipore) from total
genomic DNA, and PCR fragments gel purified prior to
cloning (Qiagen gel purification kit). BP and LR reactions
(Gateway cloning system, Invitrogen) were performed to
clone the DNA fragments upstream of an adenovirus E1b
minimal promoter and carp β-actin transcriptional start
fused to EGFP (pENTRbasEgfp) in a Tol2 plasmid back-
bone (pTolR4-R2) [32,33,49]. BP reactions were per-
formed by adding attB4 sequence to the 5' primer (5'-
GGGGACAACTTTGTATAGAAAAGTTG-gene specific
primer-3'), and attB1 sequence to the 3' primer (5'-
GGGGACTGCTTTTTTGTACAAACTTG-gene specific
primer-3'). The identity of the genomic fragments was
confirmed by restriction enzyme digests and partial
sequencing.
Injection of DNA constructs and raising of stable trans-
genic lines was performed essentially as described [33,49].
20 pg of each enhancer:EGFP-Tol2 construct was co-
injected with 20 pg of Tol2 transposase RNA in a total vol-
ume of 1 nL at the 1-cell stage. Embryos were screened for
GFP expression from 12 hpf through 96 hpf. Patterns of
enhancer expression were confirmed by multiple inde-
pendent transient injections of the plasmid (> 5 injections
for all constructs, > 100 embryos per injection), as well as
isolation of 2 or more independent stable transgenic lines
(in cases where stable transgenics were isolated).
Morpholino oligonucleotide sequences
The  lef1  and  tcf3b  splice-blocking morpholinos (MO)
were synthesized by Gene Tools (Philomath, OR); efficacy
and use were as previously described [27,28,50,51]. For
lef1, 2 ng of morpholino E7I7 was injected; for tcf3b, 5 ng
was injected.
Microscopy and image analysis
Whole-mount images were taken using brightfield micro-
scopy with embryos mounted in 80% glycerol. Confocal
microscope images of live embryos were taken after
mounting embryos anesthetized using tricaine (0.004%)
in 1.5% low melt agarose dissolved in 0.33× PBS/7.3%
glycerol. Image acquisition and analysis were performed
as described previously [52]. Confocal images of double
in situs were taken on an Olympus FV1000 after mounting
embryos in 80% glycerol. BM Purple fluorescence was
imaged with 633 nm excitation, collecting emission from
700–800 nm [53].
Sequence Analysis
We used coordinate conversion ("convert" function) in
the UCSC genome web server http://genome.ucsc.edu/BMC Developmental Biology 2008, 8:103 http://www.biomedcentral.com/1471-213X/8/103
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goldenPath/help/hgTracksHelp.html#Convert[54] to
identify conserved lef1 binding sites in the foxP2 region of
zebrafish, based on predicted Tcf4 binding sites positions
in the human genome (since Tcf4 and Lef1 bind to a
shared motif) [25]. The genomic upstream sequence of
foxP2 was obtained by performing a BLAST search against
unfinished sequences in the Sanger Centre Danio rerio
sequencing project (sequence for foxP2-enhancerA is con-
tained in BAC DKEY-116L11; GenBank accession
CU468733). To identify the sixth potential Lef1 binding
site in the foxP2-enhancerA region predicted by Hallikas
et al. [25], we used the enhancer element locator algo-
rithm (available at http://www.cs.helsinki.fi/u/kpalin/
EEL/, and compared the 9 kb regions upstream of the first
coding exon of human and zebrafish FOXP2 using the
Tcf4 consensus binding motif.
Chromatin immunoprecipitation (ChIP)
ChIP was performed as previously described [27,55] with
the following modifications. 80–120 embryos of each
genotype (wild type or homozygous Df(LG01)x8) were
collected between 28 hpf and 30 hpf, dechorionated, and
fixed in 2.2% formaldehyde for 15 minutes at room tem-
perature. Embryos were rinsed in 0.125 M glycine, fol-
lowed by PBS, and then lysed. The Df(LG01)x8 lysate was
checked by genomic PCR for the lef1 gene to confirm that
no PCR product was obtained. PCR products were visual-
ized on ethidium bromide-stained agarose gels. Primers
used for ChIP analysis of the foxP2-enhancerA.1 genomic
region were the following (forward and reverse primers,
sequences 5' to 3'): FP300, CGACTCTCCGCGAAACAC,
CATTGCCATTATCACCAGCA; FP900, CCTATCAAAG-
GCAGGCAGA, TTATCGCACTAAACAAGCTATTACAC;
FP1800, CACAGAGTGAAGTCATGGAGAAA, AGCG-
CACGCACAACTAATC; FP2700, AGAGAAACGGA-
TAAACAGTGAGAAG, CCCTCTCGAACCCTCAAAA;
B3end, TGATTAACGCCGTCTTTTCC, AGCGCACG-
CACAATAAAATA. Primers used for ChIP analysis of the
foxP2-enhancerB genomic region were (forward and
reverse primers, sequences 5' to 3'): FPb200, AGCT-
GGAAGGAAGTGTCTGG, TTTTGGCATGTGCAAAGAAG;
FPb1500, GCGTATGTATGCTTGTCAGGTT, TGCGTGGT-
GTTTTACTTGGA; FPb2600, CAGATCGACGGATGATA-
CACA, TTCCGCCAATTATCATGTCA; FPb3800,
GACCCCTTCGCAATGTCTAAT, TTCGAGAAATGCTT-
GCACAC.
Abbreviations
ChIP: chromatin immunoprecipitation; CNS: central
nervous system; MHB: mid-hindbrain boundary;
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Additional file 1
Loss of lef1 leads to absent foxP2 expression in the tectum, mid-hind-
brain boundary, and hindbrain. Whole-mount in situs at 48 hpf; ante-
rior to left, dorsal up, eyes removed. Scale bar = 50 μm. (Conditions: 
hs:Δtcf- Tg(hsp70l:Δtcf:GFP)w26, lef1 mo- lef1 morphants, wt- wild 
type, x8- homozygous Df(LG01)x8. Abbreviations: hb: hindbrain; mhb: 
mid-hindbrain boundary; tec: tectum; tel: telencephalon.) (A, B) lef1 
morphant (B) lacks expression in tectum and has diminished expression 
in the hindbrain (arrows), compared to wild-type (A). (C) In 
Df(LG01)x8 homozygote, expression is absent in the tectum and hind-
brain (arrows). (D) In Tg(hsp70l:Δtcf:GFP)w26 embryo, collected four 
hours after heat shocking, expression is absent from the tectum and hind-
brain (arrows). MHB expression is reduced but not absent, perhaps 
because lef1 induction of foxP2 expression is already sufficiently estab-
lished by the time of heat-shock.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
213X-8-103-S1.tiff]
Additional file 2
lef1 is necessary for expression from foxP2-enhancerA.1, foxP2-
enhancerB, and foxP2-enhancerD. Whole-mount confocal images at 52 
hpf (except foxP2-enhancerD), lateral view, anterior left, dorsal up. Con-
ditions (wild type- wt, or lef1 morphant- lef1 MO) are shown above the 
panels, while the enhancer name is to the left of the panels. (Abbrevia-
tions: hb: hindbrain; tec: tectum; tel: telencephalon.) (A) Tg(foxP2-
enhancerA.1:EGFP)zc44 expresses in telencephalon, tectum, and hind-
brain. (B) Tg(foxP2-enhancerA.1:EGFP)zc44 embryo injected with lef1 
morpholino: GFP expression is absent in the tectum and hindbrain 
(arrows), although telencephalic expression persists. (C) Tg(foxP2-
enhancerB:EGFP)zc41 expresses in telencephalon, tectum, and hindbrain. 
(D) Tg(foxP2-enhancerB:EGFP)zc41 embryo injected with lef1 mor-
pholino: GFP expression is absent in the hindbrain (arrow), but still 
present in the telencephalon. (E) Tg(foxP2-enhancerD:EGFP)zc47 
expresses in tectum. (F) Tg(foxP2-enhancerD:EGFP)zc47 embryo 
injected with lef1 morpholino: GFP expression is absent in the tectum 
(arrow). (G) Tg(elavl3:EGFP)zf8 embryo shows GFP expression in all 
post-mitotic neurons. (H) Tg(elavl3:EGFP)zf8 embryo injected with lef1 
morpholino: GFP expression is still present in the tectum and hindbrain. 
(I) Tg(pax2a:GFP)e1 embryo shows expression in the MHB and hind-
brain. (J) Tg(pax2a:GFP)e1 embryo injected with lef1 morpholino has 
persistent expression in the MHB and hindbrain.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
213X-8-103-S2.tiff]BMC Developmental Biology 2008, 8:103 http://www.biomedcentral.com/1471-213X/8/103
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